- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
BioLight subsidiary files IND for glaucoma treatment
BioLight Israeli Life Sciences Investments’ subsidiary, ViSci, has filed an investigational new drug (IND) application with the FDA to conduct a phase I/IIa clinical study with its treatment for glaucoma-a subconjunctival Latanoprost controlled-release insert.
Tel-Aviv, Israel-BioLight Israeli Life Sciences Investments’ subsidiary, ViSci, has filed an investigational new drug (IND) application with the FDA to conduct a phase I/IIa clinical study with its treatment for glaucoma-a subconjunctival latanoprost controlled-release insert.
The 3-month study in 68 glaucoma patients will be designed to prove the safety and efficacy of different doses of the insert containing its proprietary form of latanoprost.
Pending FDA approval, the study will be conducted at up to seven investigative sites in the United States.
Recently, ViSci has successfully completed an ocular toxicology and safety study in animals, and it holds an exclusive option from Novaer LLC to a worldwide exclusive license for any use of the insert’s controlled-release technology with any medication.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
